Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Marie Skłodowska-Curie Action · Running

GetRadi Gene Therapy of Rare Diseases

Coordinator
Kobenhavns Universitet, Denmark
Runs
1 September 2022 to 31 August 2026
Status
Running
EU funding
€2.8m
Total cost
—
Partners
15 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101072427

What the project is doing

In the project's own words, from its summary on CORDIS.

More than 300 million people worldwide are suffering from more than 6000 rare diseases. Nearly all of these rare diseases are caused by a single inherited mutation and cannot be treated effectively. Repair of the defective gene by gene editing is the only possible curative therapy. However, only for very few rare diseases such gene editing therapy has reached the clinic. The “Gene therapy of Rare Diseases” (GetRadi) consortium aims now to contribute strongly to the establishment of more gene therapies for rare diseases.

This will be accomplished by training of future leaders in gene therapy of rare diseases preforming ambitious research projects, with the following objectives: (i) Improving transfer of genome editing tools to target cells, (ii) improving gene editing efficiency, and (iii) improving safety of gene therapy. Strong participation of the pharmaceutical industry to research projects and training, development of novel in vitro and in vivo models for rare diseases to test gene therapies in relevant settings, and application of several unique genome editing tools developed by the applicants to the treatment of rare diseases are hallmarks of the network.

GetRadi brings together strong industrial beneficiaries (AstraZeneca, Miltenyi Biotec) supervising 3 ESR, highly innovative academic beneficiaries supervising 7 ESR, 3 additional industrial partners, and 4 student enrolling universities. Professional outreach training with access to widely used social media channels will be provided by the partner “European Consortium for Communicating Gene and Cell Therapy Information”.

Complementary unique expertise that is spread efficiently by network-wide training and secondments, excellent quality of supervision and intersectoral interactions, innovative transferable skill training, and efficient consortium management will result in an exceptional training of future leaders in gene therapy of rare diseases.

Who is involved

OrganisationCityCountryRole
Kobenhavns UniversitetKobenhavnDenmarkCoordinator
Univerzita KarlovaPraha 1CzechiaAssociatedpartner
Ustav Molekularni Genetiky Av Cr V.v.i.Praha 4CzechiaParticipant
Albert-Ludwigs-Universitaet FreiburgFreiburgGermanyAssociatedpartner
Charite - Universitaetsmedizin BerlinBerlinGermanyAssociatedpartner
Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc)BerlinGermanyParticipant
Miltenyi Biotec BV & Co KgBergisch GladbachGermanyParticipant
Universitaetsklinikum FreiburgFreiburgGermanyParticipant
Helsingin YliopistoHelsinkiFinlandAssociatedpartner
Universita Degli Studi Di Napoli Federico IiNapoliItalyAssociatedpartner
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Synvolux Therapeutics BVLeidenNetherlandsAssociatedpartner
Astrazeneca ABSodertaeljeSwedenParticipant
Magle Chemoswed Holding ABMalmoSwedenAssociatedpartner
The University of EdinburghEdinburghUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI